Seth Rishie M, Burger Angelika M, Kahn Harriette J
Department of Anatomic Pathology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada.
Anticancer Res. 2006 Mar-Apr;26(2A):927-31.
The HER2/neu oncogene has been reported to be amplified in > 20% of invasive ductal carcinomas. In order to investigate the HER2/neu status in pure populations of breast cancer cells, a laser capture microdissection (LCM) system was used. Formalin-fixed paraffin-embedded breast tissue areas corresponding to normal ducts, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) were microdissected and genomic DNA was isolated by a modified proteinase K- phenol extraction method and subjected to PCR for HER2/neu analysis. One hundred % concordance for detection of the HER2/neu gene amplification was found between immunohistochemistry and PCR used in combination with LCM. Our results indicated that LCM is a powerful technique for isolating pure populations of cells from paraffin-embedded tissue sections and that these cells can be used to study genomic alterations at the DNA level.
据报道,HER2/neu癌基因在超过20%的浸润性导管癌中呈扩增状态。为了研究纯乳腺癌细胞群体中的HER2/neu状态,使用了激光捕获显微切割(LCM)系统。对对应于正常导管、原位导管癌(DCIS)和浸润性导管癌(IDC)的福尔马林固定石蜡包埋乳腺组织区域进行显微切割,并通过改良的蛋白酶K - 酚提取法分离基因组DNA,然后进行PCR以分析HER2/neu。发现免疫组织化学与结合LCM使用的PCR在检测HER2/neu基因扩增方面的一致性为100%。我们的结果表明,LCM是从石蜡包埋组织切片中分离纯细胞群体的强大技术,并且这些细胞可用于在DNA水平研究基因组改变。